Tasigna (Nilotinib HCl) Patent Expiration, LOE Window & CMS Spending
Tasigna (Nilotinib HCl) by Novartis: FDA Orange Book core substance LOE 2032-10-07, 6 AB generics, $521.2M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N022068 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-10-07 |
| Last Listed Patent or Exclusivity Date | 2032-10-07 |
| Orange Book Patents (*PED Extensions) | 12 patents (6 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $521.2M |
| 2024 Medicare Part D Spend | $427.0M |
| 2024 Medicaid Spend | $94.2M |
| Reported Wholesale Price Change (CA SB 17) | 12 WAC filings (max 27.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.